Business Description
Oncodesign Precision Medicine SA
ISIN : FR001400CM63
Total Employee Number:
13Compare
Compare
Traded in other countries / regions
ALOPM.FranceZR8.Germany IPO Date
2022-10-05Description
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 3.53 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | 1.05 | |||||
Interest Coverage | 44.42 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.04 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69.2 | |||||
3-Year Book Growth Rate | 60.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.34 | |||||
9-Day RSI | 51.4 | |||||
14-Day RSI | 44.16 | |||||
3-1 Month Momentum % | -28.34 | |||||
6-1 Month Momentum % | -58.45 | |||||
12-1 Month Momentum % | -14.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.76 | |||||
Quick Ratio | 1.01 | |||||
Cash Ratio | 0.76 | |||||
Days Sales Outstanding | 629.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | 19.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 3728.35 | |||||
Operating Margin % | 3148.66 | |||||
Net Margin % | 2099.62 | |||||
EBITDA Margin % | 2321.07 | |||||
ROE % | 26.16 | |||||
ROA % | 36.3 | |||||
ROIC % | 89.98 | |||||
3-Year ROIIC % | 102.74 | |||||
ROC (Joel Greenblatt) % | 82.24 | |||||
ROCE % | 46.69 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1.14 | |||||
Forward PE Ratio | 0.08 | |||||
PE Ratio without NRI | 0.84 | |||||
PS Ratio | 22.87 | |||||
PB Ratio | 0.12 | |||||
Price-to-Tangible-Book | 0.12 | |||||
EV-to-EBIT | 1.89 | |||||
EV-to-EBITDA | 1.78 | |||||
EV-to-Revenue | 41.32 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Graham-Number | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 0.12 | |||||
| Price-to-Net-Cash | 0.16 | |||||
Earnings Yield (Greenblatt) % | 52.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncodesign Precision Medicine SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.261 | ||
| EPS (TTM) (€) | 0.302 | ||
| Beta | -0.1242 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.72 | ||
| Volatility % | 66.16 | ||
| 14-Day RSI | 44.16 | ||
| 14-Day ATR (€) | 0.013542 | ||
| 20-Day SMA (€) | 0.34145 | ||
| 12-1 Month Momentum % | -14.88 | ||
| 52-Week Range (€) | 0.31 - 0.92 | ||
| Shares Outstanding (Mil) | 19.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncodesign Precision Medicine SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncodesign Precision Medicine SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncodesign Precision Medicine SA Frequently Asked Questions
What is Oncodesign Precision Medicine SA(XPAR:ALOPM)'s stock price today?
The current price of XPAR:ALOPM is €0.34. The 52 week high of XPAR:ALOPM is €0.92 and 52 week low is €0.31.
When is next earnings date of Oncodesign Precision Medicine SA(XPAR:ALOPM)?
The next earnings date of Oncodesign Precision Medicine SA(XPAR:ALOPM) is .
Does Oncodesign Precision Medicine SA(XPAR:ALOPM) pay dividends? If so, how much?
Oncodesign Precision Medicine SA(XPAR:ALOPM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Oncodesign Precision Medicine SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers